Welcome to our dedicated page for WORK Medical Technology Group SEC filings (Ticker: WOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The WORK Medical Technology Group LTD (WOK) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a foreign private issuer in the medical devices sector. WORK Medical files annual reports on Form 20-F and current reports on Form 6-K, detailing its operations in developing and manufacturing Class I and II medical devices and selling Class I and II disposable medical devices through subsidiaries in China.
In these filings, investors can review information on WORK Medical’s product portfolio of medical consumables and equipment, its sales footprint across 34 provincial-level administrative regions in China, and the registration of 17 products with the U.S. Food and Drug Administration. Form 6-K reports provide updates on interim financial statements and management’s discussion and analysis, extraordinary general meetings and voting results, changes in independent auditors, and capital markets transactions such as registered direct offerings, at-the-market sales agreements, and pre-funded warrants.
Filings also describe share structure changes and Nasdaq listing matters, including approved share consolidations (reverse stock splits), increases in authorized share capital, and correspondence with Nasdaq regarding minimum bid price compliance and potential delisting determinations. These documents outline the reasons for share consolidations, effective dates, and post-consolidation share counts, giving context to changes in the company’s capital structure.
On Stock Titan, users can access WORK Medical’s Forms 6-K and 20-F as they are furnished to the SEC’s EDGAR system, along with AI-powered summaries that highlight key points such as financing terms, governance changes, and listing status updates. The filings page is also a reference point for tracking any future registration statements, prospectus supplements, and other transactional documents that the company incorporates by reference into its shelf registration statements.
WORK Medical Technology Group LTD disclosed that Wu Zhenguo, a company director, has filed an initial Form 3 insider ownership statement. The structured data shows no reported stock purchases, sales, option exercises, or other transactions in this filing, indicating it is a baseline disclosure of his status as a director.
WORK Medical Technology Group LTD director and COO Yu Baiming filed an initial ownership report showing indirect holdings of Class B Ordinary Shares. The filing reports beneficial ownership of 100,625 Class B Ordinary Shares held indirectly through LWY GROUP LTD, with no buy or sell transactions reported.
WORK Medical Technology Group LTD director and CEO Wu Shuang Jarod has filed an initial Form 3, which is a statement of beneficial ownership for insiders. This filing does not list any stock transactions or holdings details and simply establishes him as a reporting insider for WOK.
WORK Medical Technology Group LTD submitted an initial insider ownership report for director Lin Qisheng on Form 3. The data provided shows no reportable transactions, no listed holdings, and no derivative positions for this reporting person at the time of the filing.
WORK Medical Technology Group LTD reported that Liang Ningfang, the company’s Chief Financial Officer, has filed an initial statement of beneficial ownership on Form 3. This filing establishes Liang’s status as an insider of WORK Medical but does not report any share transactions or holdings details in the provided data.
WORK Medical Technology Group Ltd has created a wholly-owned New Zealand subsidiary, WORK MEDICAL TECHNOLOGY LIMITED, which will act as its operations and management headquarters and help expand business in New Zealand and Australia. The company now lists its principal executive offices at 1/88 Cook Street in Auckland, New Zealand, and the prior executive office in China is no longer treated as a principal executive office.
This update is furnished on a Form 6-K and is incorporated by reference into the company’s existing Form F-3 registration statement, becoming part of that shelf registration from the date of filing.
WORK Medical Technology Group LTD reports a change in its board of directors. On March 23, 2026, independent director Xiaoyang Li resigned from the Board, the Audit, Compensation, and Nominating and Corporate Governance Committees, and as chairperson of the Compensation Committee, citing personal reasons.
To fill this vacancy, the Board appointed Dr. Qisheng Lin as an independent director, a member of all three committees, and chairperson of the Compensation Committee, effective the same day. Dr. Lin is a nephrology specialist and academic with roles at Renji Hospital and prior research experience at the Icahn School of Medicine at Mount Sinai. The Board determined he meets the Nasdaq “independent director” standard. This report is incorporated by reference into the Company’s Form F-3 registration statement (File No. 333-289943).
WORK Medical Technology Group LTD filed Amendment No. 1 to its Form 20-F as an exhibit-only update. The amendment’s sole purpose is to add Exhibit 15.2 and Exhibit 15.3, which are consents from its independent auditors, WWC, P.C. and HTL International, LLC.
The company states that no other changes were made to the previously filed annual report for the year ended September 30, 2025, and that this amendment does not update any disclosures or reflect later events. As of September 30, 2025, the company had 95,998,776 Class A and 7,592,500 Class B ordinary shares outstanding.
WORK Medical Technology Group reported that shareholders approved all 13 proposals at the annual general meeting, with 2,064,443 votes represented, about 56.73% of total votes as of January 30, 2026.
Shareholders approved a major share capital reorganization. The authorized share capital was first increased to US$100,000,000,000 divided into 16,000,000,000 Class A and 4,000,000,000 Class B ordinary shares, each with a par value of US$5.00. They then approved a reduction of the par value of each issued Class A and Class B share from US$5.00 to US$0.00001, transferring the resulting credit to a distributable reserve that may be used as permitted by law, including offsetting accumulated losses. Following related subdivision and cancellation steps, the authorized share capital will be US$200,000 divided into 16,000,000,000 Class A and 4,000,000,000 Class B ordinary shares, each with a par value of US$0.00001.
Shareholders also authorized a future share consolidation, allowing the board, within two years, to consolidate each 4,000 shares, or a lesser whole share amount not fewer than 2, into 1 share, with fractional entitlements rounded up. Several amended and restated memoranda of association to reflect the capital changes and consolidation were approved. All nominated directors, including LI Xiaoyang and WU Shuang, were re-elected, HTL International, LLC was confirmed as auditor for the fiscal year ending September 30, 2026, and authority to adjourn the meeting if needed was ratified.
WORK Medical Technology Group LTD has called an annual general meeting on February 25, 2026 for shareholders of its Class A and Class B ordinary shares. Investors are being asked to approve a major change to the capital structure, increasing authorized share capital from US$100,000,000 (16,000,000 Class A and 4,000,000 Class B shares at US$5.00 par) to US$100,000,000,000 (16,000,000,000 Class A and 4,000,000,000 Class B shares at US$5.00 par).
The company also seeks a share capital reduction and reorganization, cutting par value on issued shares from US$5.00 to US$0.00001 and ultimately resetting authorized share capital to US$200,000 divided into 16,000,000,000 Class A and 4,000,000,000 Class B shares at US$0.00001 par. The board further requests authority to implement, within two years, a share consolidation (reverse split) of between 2-for-1 and up to 4,000-for-1, mainly to help maintain compliance with Nasdaq’s minimum bid-price rules.
Shareholders will also vote on adopting amended and restated memoranda of association to reflect the capital changes, re-electing five current directors, re-appointing HTL International, LLC as auditor for the year ending September 30, 2026, and granting the board power to adjourn the meeting if more time is needed to secure approvals.